Integrating multiparametric prostate MRI into clinical practice

Cancer Imaging

Volumn 11, Issue SPEC. ISS. A, 2011, Pages

  Padhani, A R ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRACTICE GUIDELINE; PROSTATE CANCER; MALE; METHODOLOGY; PROSTATE TUMOR; REVIEW;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS;

EID: 84866757519     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.9007     Document Type: Article

References (43)

1. Tan CH, Wang J, Kundra V. Diffusion weighted imaging in prostate cancer. Eur Radiol 2011; 21: 593-603. doi:10.1007/ s00330-010-1960-y.
2. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007; 63: 335-50. doi:10.1016/j.ejrad.2007.06.028. (Pubitemid 47321040)
3. Verma S, Rajesh A, Futterer JJ, et al. Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 2010; 194: 1414-26. doi:10.2214/AJR.10.4312.
4. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2009; 77: 340-5. doi:10.1016/j.ejrad.2009.08.007.
5. Westphalen AC, Coakley FV, Qayyum A, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008; 246: 177-84. doi:10.1148/radiol. 2453062042. (Pubitemid 350305041)
6. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-33. doi:10.1148/radiol.2511080409.
7. Pondman KM, Futterer JJ, ten Haken B, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 2008; 54: 517-527. doi:10.1016/ j.eururo.2008.06.001.
8. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495. doi:10.1148/radiol.10100667.
9. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009; 182: 1371-1377. doi:10.1016/j.juro.2009.06.035.
10. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2011.
11. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255: 89-99. doi:10.1148/ radiol.09090475.
12. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009; 103: 730-733. doi:10.1111/j.1464-410X.2008.08205.x.
13. Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008; 63: 871-879. doi:10.1016/ j.crad.2007.10.020.
14. Ahmed HU, Emberton M. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009; 104: 269-270; author reply 270.
15. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183: 520-527. doi:10.1016/j.juro.2009.10.022.
16. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008; 72: S12-24. doi:10.1016/j.urology.2008.10.004.
17. de la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol 2010; 24: 775-780. doi:10.1089/end.2009.0596.
18. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-269. doi:10.1016/ S0090-4295(02)01728-4. (Pubitemid 34831770)
19. Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol 2011; 8: 48-55. doi:10.1038/nrclinonc-.2010.190.
20. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 2007; 188: 812-816. doi:10.2214/ AJR.06.0165.
21. Amsellem-Ouazana D, Younes P, Conquy S, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005; 47: 582-586. doi:10.1016/j.eururo.2005.01. 015. (Pubitemid 40521900)
22. Prando A, Kurhanewicz J, Borges AP, Oliveira EM, Jr. Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 903-910. doi:10.1148/ radiol.2363040615. (Pubitemid 41170854)
23. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259: 162-172. doi:10.1148/ radiol.10101251.
24. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458. doi:10.1148/radiol. 2412051866. (Pubitemid 44632891)
25. Mazaheri Y, Shukla-Dave A, Hricak H, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008; 246: 480-488. doi:10.1148/ radiol.2462070368.
26. Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257: 715-723. doi:10.1148/radiol.10100021.
27. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494. doi:10.1016/ j.eururo.2010.12.009.
28. Mueller-Lisse U, Scheidler J, Klein G, Reiser M. Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists. Eur Radiol 2005; 15: 1826-1833. doi:10.1007/s00330- 005-2695-z. (Pubitemid 41222888)
29. Nogueira L, Wang L, Fine SW, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 2010; 75: 472-477. doi:10.1016/j.urology.2009.04.061.
30. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-2437. doi:10.1016/j.juro.2006.08. 007. (Pubitemid 44665992)
31. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010; 106: 991-997. doi:10.1111/j.1464-410X.2010.09291.x.
32. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708. doi:10.1148/radiol.2333030672.
33. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106: 1607-1611. doi:10.1111/j.1464-410X.2010. 09436.x.
34. Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007; 42: 116-122. doi:10.1097/01.rli.0000251541.03822.bb. (Pubitemid 46104892)
35. King CR, Ferrari M, Brooks JD. Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol 2009; 27: 592-597. doi:10.1016/j.urolonc.2008.05.009.
36. Sakai I, Harada K, Kurahashi T, Yamanaka K, Hara I, Miyake H. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones. Int J Urol 2006; 13: 368-372. doi:10.1111/j.1442-2042.2006.01307.x. (Pubitemid 43827986)
37. Yagci AB, Ozari N, Aybek Z, Duzcan E. The value of diffusionweighted MRI for prostate cancer detection and localization. Diagn Interv Radiol 2010.
38. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF, 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010; 194: W316-322. doi:10.2214/ AJR.09.2651.
39. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008; 27: 132-139. doi:10.1002/jmri.21181.
40. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28: 720-726. doi:10.1002/jmri.21503.
41. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-461. doi:10.1148/ radiol.11091409.
42. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814. doi:10.1148/radiol.2343040363. (Pubitemid 40250824)
43. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259: 775-784. doi:10.1148/radiol.11102066.